p38丝裂原活化蛋白激酶抑制剂研究进展

被引：63

作者：

王国军 ^{[1
,2
]}

刘亚伟 ^{[2
]}

李玉花 ^{[1
]}

姜勇 ^{[2
]}

机构：

[1] 东北林业大学生命科学学院

[2] 南方医科大学广东省功能蛋白质组学重点实验室

来源：

生物技术通讯 | 2009年 / 20卷 / 03期

基金：

广东省科技计划;

关键词：

p38丝裂原活化蛋白激酶通路; p38抑制剂; 炎症;

D O I：

暂无

中图分类号：

R98 [各科药物];

学科分类号：

100705 [微生物与生化药学];

摘要：

p38丝裂原活化蛋白激酶(MAPK)通路是细胞内应激反应信号通路,与炎症反应密切相关。炎症反应失控是很多疾病产生的重要原因之一,传统抗炎药物的严重副作用使得寻找强效、安全的抗炎药物极为迫切。通过抑制剂调节信号通路的炎症药物研发成为目前发展的趋势,而p38MAPK的中心地位使其成为首选靶点。p38MAPK抑制剂和p38MAPK的研究进展相辅相成,发展迅速。已报道的100多种不同化学结构的p38MAPK特异性抑制剂中已有20多种进入临床试验阶段,但至今尚没有一种化合物被批准应用于临床治疗。我们讨论了p38MAPK抑制剂的研究现状和研究策略。

引用

页码：399 / 403

页数：5

共 19 条

[1]

RWJ 67657; a potent; orally active inhibitor of p38 mitogen-activated protein kinase..Wadsworth S A; Cavender D E; Beers S A; et al;.J Pharmacol Exp Ther.1999,

[2]

Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity [J].

Angell, Richard ;

Aston, Nicola M. ;

Bamborough, Paul ;

Buckton, Jacky B. ;

Cockerill, Stuart ;

deBoeck, Suzanne J. ;

Edwards, Chris D. ;

Holmes, Duncan S. ;

Jones, Katherine L. ;

Laine, Dramane I. ;

Patel, Shila ;

Smee, Penny A. ;

Smith, Kathryn J. ;

Somers, Don O. ;

Walker, Ann L. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (15) :4428-4432

[3]

The discovery of (R)-2-(sec-butylamino)-N(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994) -: A potent and efficacious p38α MAP kinase inhibitor [J].

Hynes, John, Jr. ;

Wu, Hong ;

Pitt, Sidney ;

Shen, Ding Ren ;

Zhang, Rosemary ;

Schieven, Gary L. ;

Gillooly, Kathleen M. ;

Shuster, David J. ;

Taylor, Tracy L. ;

Yang, XiaoXia ;

McIntyre, Kim W. ;

McKinnon, Murray ;

Zhang, Hongjian ;

Marathe, Punit H. ;

Doweyko, Arthur M. ;

Kish, Kevin ;

Kiefer, Susan E. ;

Sack, John S. ;

Newitt, John A. ;

Barrish, Joel C. ;

Dodd, John ;

Leftheris, Katerina .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) :1762-1767

[4]

Targeting the unactivated conformations of protein kinases for small molecule drug discovery [J].

Alton, Gordon R. ;

Lunney, Elizabeth A. .

EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (06) :595-605

[5]

Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs [J].

Ozdemir, Cevdet ;

Akdis, Cezmi A. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (09) :1327-1344

[6]

Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways [J].

Malemud, Charles J. .

CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (03) :339-343

[7]

Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells [J].

Bagley, Mark C. ;

Davis, Terence ;

Dix, Matthew C. ;

Rokicki, Michal J. ;

Kipling, David .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (18) :5107-5110

[8]

Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects [J].

Pei, Yong ;

Harvey, Anita ;

Yu, Xiao-Peng ;

Chandrasekhar, Srinivasan ;

Thirunavukkarasu, Kannan .

OSTEOARTHRITIS AND CARTILAGE, 2006, 14 (08) :749-758

[9]

p38 MAP kinase inhibitors: A future therapy for inflammatory diseases.[J].Ruth J. Mayer;James F. Callahan.Drug Discovery Today: Therapeutic Strategies.2006, 1

[10]

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: A randomized, double-blind, placebo-controlled trial [J].

Schreiber, S ;

Feagan, B ;

D'Haens, G ;

Colombel, JF ;

Geboes, K ;

Yurcov, M ;

Isakov, V ;

Golovenko, O ;

Bernstein, CN ;

Ludwig, D ;

Winter, T ;

Meier, U ;

Yong, C ;

Steffgen, J .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (03) :325-334

← 1 2 →